Amedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amedisys Reports Third Quarter 2018 Financial Results and Updates 2018 Guidance
October 29, 2018 5:00 PM EDTBATON ROUGE, La., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month period ended September 30, 2018.
Three Month Periods Ended September 30, 2018 and 2017
Net service revenue increased $43.6Â million to $417.3Â million compared to $373.7Â million in 2017 (1).Net income attributable to Amedisys, Inc. of $31.4Â million compared to $14.6Â million in 2017.Net income attributable to Amedisys, Inc. per diluted share of $0.96 per diluted share compared to $0.42 in 2017.Adjusted Quarterly Results*
Adjusted EBITDA of $45.3Â million compared to $36.9Â million in 2017.Adjusted net service... More